Voyageur Pharmaceuticals recorded three recent insider transactions involving sales totaling 3.28 billion KRW. These divestments by non-registered executives occurred following a 33.3% decline in stock value over the past quarter. The company's next scheduled results financiers are anticipated in April 2027, while current market pricing remains near the lower end of its annual range.